Biogen has until 2030 to prove that their newly approved Alzheimer's drug, Aduhelm, actually works as part of FDA conditional approval
The House Committee on Oversight and Reform and the House Committee on Energy and Commerce have launched an investigation into the controversial approval of Aduhelm
The drug received approval despite mixed clinical trials results, though it did show it could potentially reduce cognitive decline by 22%
Lawmakers are concerned about the drug's steep price tag, that will cost $56,000 per year of treatment
The FDA has defended its decision to approve Aduhelm, saying it is 'reasonably likely' to help Alzheimer's patients
Three members of FDA advisory board stepped down after approval, one calling it 'worst drug approval decision in recent U.S. history'
